Literature DB >> 8492237

Which antiemetic?

I Lichter1.   

Abstract

The choice of antiemetic should not be arbitrary, but should be based on knowledge of the different pathways of the various stimuli that lead to nausea and vomiting and the neuroreceptors involved. The steps to be taken in choosing an appropriate antiemetic are described. They are (a) to establish the probable cause of the nausea and vomiting, (b) to consider the afferent pathways involved, (c) to define the neuroreceptors activated at each of these sites, (d) to select the group of antiemetics that antagonizes these neuroreceptors, and (e) to choose the most potent antiemetic with the fewest side effects in that group. Causes for failure to respond to a chosen antiemetic are considered and the action to be taken is described.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492237

Source DB:  PubMed          Journal:  J Palliat Care        ISSN: 0825-8597            Impact factor:   2.250


  4 in total

Review 1.  Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer.

Authors:  Paul Glare; Glenn Pereira; Linda J Kristjanson; Martin Stockler; Martin Tattersall
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

Review 2.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

3.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

4.  Sublingually administered scopolamine for nausea in terminally ill cancer patients.

Authors:  Kengo Imai; Masayuki Ikenaga; Tomoyuki Kodama; Seitetsu Kanemura; Keiko Tamura; Tatsuya Morita
Journal:  Support Care Cancer       Date:  2013-05-31       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.